Int. Immunopharmacol.

Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients.

Eltahir M, Fletcher E, Dynesius L, ..., Mattsson M, Mangsbo SM

Int. Immunopharmacol. 90 (-) 107226 [2021-01-00; online 2020-12-11]

Nanomedicine for improvement of dendritic cell-based cancer immunotherapy.

Hashemi V, Farhadi S, Ghasemi Chaleshtari M, ..., Ghalamfarsa G, Jadidi-Niaragh F

Int. Immunopharmacol. 83 (-) 106446 [2020-06-00; online 2020-03-31]

Extracorporeal human whole blood in motion, as a tool to predict first-infusion reactions and mechanism-of-action of immunotherapeutics.

Fletcher EAK, Eltahir M, Lindqvist F, ..., Leja-Jarblad J, Mangsbo SM

Int. Immunopharmacol. 54 (-) 1-11 [2018-01-00; online 2017-10-27]

Affiliated researcher

CCL2 mediates anti-fibrotic effects in human fibroblasts independently of CCR2.

Kalderén C, Stadler C, Forsgren M, ..., Sydow-Bäckman M, Svensson Gelius S

Int. Immunopharmacol. 20 (1) 66-73 [2014-05-00; online 2014-02-26]